Table 1 AGDS discontinuation prevalence and demographics across medications
Antidepressant | Total discontinuation including both sexes (%) | Controls males (%) | Discontinuation males (%) | Controls females (%) | Discontinuation females (%) | Controls mean age (std) | Discontinuation mean age (std; t; p-value) |
|---|---|---|---|---|---|---|---|
Sertraline | 2870 (44.7) | 738 (54.2) | 624 (45.8) | 2813 (55.6) | 2246 (44.4) | 41 (14) | 41 (14; 1.65; 0.10) |
Escitalopram | 1896 (38.9) | 674 (62.2) | 410 (37.8) | 2310 (60.9) | 1486 (39.1) | 38 (13) | 37 (13; − 4.11; 0.00) |
Venlafaxine | 2017 (43.9) | 639 (55.2) | 518 (44.8) | 1936 (56.4) | 1499 (43.6) | 43 (14) | 43 (14; − 0.57; 0.57) |
Amitriptyline | 814 (51.6) | 176 (50.4) | 173 (49.6) | 586 (47.8) | 641 (52.2) | 46 (14) | 45 (15; − 0.73; 0.47) |
Mirtazapine | 1258 (57.3) | 338 (50.4) | 333 (49.6) | 598 (39.3) | 925 (60.7) | 44 (14) | 41 (14; − 4.05; 0.00) |
Desvenlafaxine | 1078 (38.4) | 417 (61.8) | 258 (38.2) | 1310 (61.5) | 820 (38.5) | 39 (13) | 38 (13; − 2.39; 0.02) |
Citalopram | 1139 (44.4) | 325 (55.7) | 258 (44.3) | 1099 (55.5) | 881 (44.5) | 43 (13) | 41 (13; − 3.01; 0.00) |
Fluoxetine | 1774 (46.3) | 418 (52.5) | 378 (47.5) | 1643 (54.1) | 1396 (45.9) | 40 (15) | 41 (15; 0.98; 0.33) |
Duloxetine | 971 (42.3) | 292 (56.7) | 223 (43.3) | 1034 (58.0) | 748 (42.0) | 41 (14) | 40 (14; − 2.67; 0.01) |
Paroxetine | 794 (47.7) | 228 (55.3) | 184 (44.7) | 644 (51.4) | 610 (48.6) | 46 (13) | 45 (14; − 0.73; 0.46) |